HD 10019
Alternative Names: HD-10019Latest Information Update: 18 Dec 2024
Price :
$50 *
At a glance
- Originator UCSF; University of Arkansas for Medical Sciences
- Developer Harmonic Discovery
- Class Antineoplastics; Small molecules
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Acute myeloid leukaemia
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 23 Oct 2024 Pharmacokinetics and pharmacodynamics data from a preclinical studies in Acute myeloid leukemia presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR -2024)
- 05 Feb 2024 HD 10019 is available for licensing as of 05 Feb 2024. https://www.harmonicdiscovery.com/partnerships
- 03 Feb 2024 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route)